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COST-EFFECTIVENESS OF RABEPRAZOLE 
VERSUS RANITIDINE IN REFLUX ESOPHAGITIS
Ofman JJ1, Yamashita BD2, Siddique RS3, Larson LR2, Willian 
MK3
1Cedars Sinai/Zynx Health Inc., Los Angeles, CA, USA; 
2Ovation Research Group, Highland Park, IL, USA; 3Janssen 
Pharmaceutica, Titusville, NJ, USA
OBJECTIVE: Compare cost-effectiveness of rabeprazole
(RAB) versus ranitidine (RAN) in acute and maintenance
therapy of erosive esophagitis using symptom response,
rather than endoscopic healing, as the outcome.
METHODS: Cost-effectiveness was assessed in a decision
analysis model based on clinical-trial and published data.
Costs reflected 1998 Medicare reimbursement, generic
RAN, and estimated AWP for RAB. Cost per symptom-
atic recurrence prevented over 1 year of maintenance ther-
apy is reported as average and incremental cost-effective-
ness ratios (ACER, ICER). Patients were initially treated
with RAB 20 mg QD or RAN 150 mg QID for 8 weeks.
Asymptomatic RAB patients received RAB 20 mg QD
maintenance, while asymptomatic RAN patients received
RAN 150 mg BID. Symptomatic RAB patients received
dose escalation, and symptomatic RAN patients were
switched to RAB therapy. Non-responders were evaluated
for surgery. Recurrences were treated with RAB 40 mg or
RAN 300 mg BID. If RAN patients required RAB for
acute therapy, they received RAN 300 BID maintenance.
Symptomatic recurrences on RAN 300mg BID mainte-
nance were treated with RAB, followed with RAB mainte-
nance. Up to two symptomatic recurrences were allowed.
RESULTS: Average per-patient costs were higher with
RAB (RAB $2020 versus RAN $1917). RAB, however,
prevented more symptomatic recurrences (RAB 74% ver-
sus RAN 41%; ACER RAB $2748/recurrence prevented
versus RAN $4719/recurrence prevented). Excess physi-
cian visits and procedures with RAN offset RAB’s higher
cost. In sensitivity analysis, RAB remained more cost-
effective than RAN despite varying key clinical and cost
variables / 20%. The ICER of preventing one addi-
tional symptomatic recurrence with RAB rather than
RAN is $313.
CONCLUSION: RAB may be a cost-effective alternative
to RAN when modeling symptom relief in the manage-
ment of erosive esophagitis.
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TREATMENT OF DIABETIC FOOT ULCERS 
WITH TOPICAL RECOMBINANT GROWTH 
FACTOR GEL ACHIEVES HIGHER HEALING 
RATES AND RESULTS IN LOWER PROJECTED 
COSTS OF CARE
Martens L1, Zagari M1, Gagnon D1, Wieman TJ2
1ICOM Health Economics, Johnson & Johnson, Raritan, NJ, 
USA; 2Department of Surgical Oncology, University of 
Louisville, Louisville, KY, USA
OBJECTIVE: Diabetic foot ulcers are associated with
many adverse health outcomes and high treatment costs.
Wound infections, osteomyelitis, and amputations con-
tribute to wound-related costs of $4000 to $10,000 for an
episode of treatment, costs which may be partially avoided
with better wound management and improved healing
rates. Becaplermin gel, an FDA-approved topical recombi-
nant growth factor gel, has been shown to increase the in-
cidence of complete healing of full thickness, neuropathic,
diabetic foot ulcers (50% of patients treated with beca-
plermin gel plus good wound care versus 35% of patients
treated with placebo gel plus good wound care).
METHODS: A separate economic analysis was per-
formed for clinical trial data (20 weeks plus 12 weeks of
follow-up) using resource utilization determined from the
trial. Unit costs of resources were assigned from private
and US governmental cost databases. A state-transition
model was used to project resource use in the weeks fol-
lowing the clinical trial, up to 1 year.
RESULTS: After 20 weeks, average per-patient costs for
the control versus becaplermin gel groups were $4466
and $4817, respectively. Patients treated with becapler-
min gel had fewer hospitalizations, fewer outpatient vis-
its, and fewer debridements, but higher drug costs. By 29
weeks, treatment with becaplermin gel resulted in lower
projected overall treatment costs. Average per-patient
costs after 52 weeks were $10,416 (control) versus $9289
(becaplermin gel).
CONCLUSIONS: The analysis suggests that achieving a
better healing rate results in fewer overall resources used
and, consequently, lower projected costs of care.
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INCREASED UPPER GASTROINTESTINAL (UGI) 
DISTRESS AMONG ARTHRITIS PATIENTS 
TREATED WITH NSAIDS AS COMPARED TO 
CELECOXIB AND PLACEBO
Burke TA2, Goldstein JL1, Pettitt AD3, Maurath CJ2, Zhao SZ2, 
Zabinski RA2
1University of Illinois at Chicago, Chicago, IL, USA; 
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Upper gastrointestinal (UGI) symptoms are commonly
reported side effects in non-steroidal anti-inflamatory
(NSAID) users, often requiring physician intervention and
utilization of healthcare resources (e.g., endoscopy, acid-
suppression therapy). We hypothesize that a medication
associated with fewer UGI symptoms will result in signif-
icant clinical and healthcare utilization advantages over
existing NSAIDs.
OBJECTIVE: Quantify clinically significant UGI distress
among patients treated with celecoxib, a novel COX-2
inhibitor, compared to NSAIDs and placebo.
METHODS: Combined data from eight blinded celecoxib
phase III clinical trials of at least 12-weeks duration were
used (# subjects): celecoxib (3216), placebo (1136), and
NSAIDs (2427), divided among naproxen (1366), ibupro-
fen (345), and diclofenac (716). A composite UGI-symp-
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tom measure, UGI distress, was developed using WHO
adverse event codes (abdominal pain, nausea, and dyspep-
sia). To simulate clinically significant adverse events re-
quiring medical intervention, only moderate (some limita-
tion of activities) and severe (inability to carry out
activities) events were included. Survival analysis was
used to calculate the cumulative percentage of patients
with UGI distress over a 12-week period.
RESULTS: Kaplan-Meier curves revealed a significant
difference (p  0.01) between NSAIDs compared to pla-
cebo and/or celecoxib. At 12 weeks, the cumulative prob-
ability of patients to have UGI distress were: NSAIDs
(12.9%), celecoxib (8.1%), and placebo (8.5%) (p 
0.01 for NSAIDs versus celecoxib or placebo; p  NS for
celecoxib versus placebo).
CONCLUSION: NSAID-treated patients experience sig-
nificant UGI distress beyond the background rate of UGI
distress, as represented by placebo. These results demon-
strate the clinical advantage of celecoxib over existing
NSAIDs and suggest a potential healthcare utilization ad-
vantage due to decreased frequency of UGI distress and
need for physician intervention.
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CEFPODOXIME PROXETIL 100mg VERSUS 
CEFPODOXIME PROXETIL 200mg IN THE 
TREATMENT OF ACUTE BACTERIAL 
EXACERBATION OF CHRONIC BRONCHITIS IN 
ADULT PATIENTS
Wilson JP1, Johnsrud MT1, Shepherd MD1, Pleil AM2
1University of Texas, Austin, TX, USA;
2Pharmacia & Upjohn AB, Stockholm, Sweden
OBJECTIVE: To compare the efficacy and economic
outcomes related to the treatment of acute bacterial exac-
erbation of chronic bronchitis in adult patients treated
with either: 1) cefpodoxime proxetil 100mg, or 2) cefpo-
doxime proxetil 200mg twice daily for 14 days.
METHODS: The cefpodoxime proxetil arms of a multi-
center, randomized, observer-blinded, parallel-group an-
tibiotic trial were evaluated. A total of 117 patients com-
pleted the study (100mg n  58, 200mg n  59). Direct
and indirect costs related to the infection and its treat-
ment were collected over the course of the study, includ-
ing additional office visits, lab tests and procedures, and
indirect costs related to productivity changes at work and
social hours lost due to the illness.
RESULTS: There were no significant differences between
the 100mg and 200mg groups with regards to bacterial
cure rates (89.7% and 89.8%, respectively), mean per-
cent of total work hours lost (16.91 [15.67] and 20.47
[27.41], respectively [p  0.597], and mean percent of
total social hours lost (10.71 [12.69] and 9.55 [9.67], re-
spectively [p  0.690]). Furthermore, there were no prac-
tical differences in the additional healthcare utilization
and number of medical events related to the drug ther-
apy. Mean study medication costs were significantly
lower (p  0.001) for the 100mg group ($66.70 [$6.80])
when compared to the 200mg group ($93.80 [$5.72]).
CONCLUSIONS: Because there were no significant dif-
ferences in the clinical outcomes, additional health utili-
zation and medical events, and work and social hours
lost when comparing the two treatment regimens, the use
of cefpodoxime proxetil 100mg provided cost-minimiza-
tion over cefpodoxime proxetil 200mg in the treatment
of acute bacterial exacerbation of chronic bronchitis in
adult patients.
QUALITY OF LIFE INSTRUMENTS
TPQL1
DEVELOPMENT AND PSYCHOMETRIC 
VALIDATION OF A QUALITY OF LIFE 
QUESTIONNAIRE IN URINARY
INCONTINENCE (CONTILIFE®)
Girod I
Mapi Values, Lyon, France
OBJECTIVES: To develop and validate a disease-specific
questionnaire to measure the impact of urinary inconti-
nence (UI) in women’s quality of life (QoL). This ques-
tionnaire is aimed at measuring all types of incontinence
in clinical trials. A urinary urge incontinence (UUI) ques-
tionnaire already available and fully validated was used
as a basis.
METHODS: 1) Identification of additional measurement
concepts, during 12 interviews. 2) Item generation fol-
lowing the existing questionnaire format. 3) Content and
face validity in additional interviews. 4) Cross-sectional
validation study: to allow item reduction (based on ho-
mogeneity of the domains, item rank and fit in the Rasch
modeling), to assess the construct validity (multitrait
analysis), internal consistency and clinical validity. 5)
Test-retest reliability study.
RESULTS: In this study 104 patients with urge, stress,
and mixed UI filled in the specific questionnaire once. Pa-
tients were 50 years old on average, 40% had urge-related
urinary leakage several times a week, 34% had micturi-
tions at night, 73% had stress-related leakage during light
and moderate efforts. The initial 50-item questionnaire
was reduced to 28 items gathered in six dimensions: daily
activities, effort situation, self-image, emotional impact,
sexuality, and global QoL. Item grouping hypotheses
proved relevant based on item convergent and divergent
validity and internal reliability (Cronbach’s alpha 
0.76). Clinical validity was demonstrated by the signifi-
cant impairment of QoL in patients reporting urinary
leaks, greater urge-related and stress-related urinary
handicap (p  0.0005). Fifty-eight stable women filled in
the questionnaire twice. Intraclass Correlation Coeffi-
cients ranged from 0.87 to 0.94, showing good test-retest
reproducibility.
